Izquierdo CLM, Espinosa EEE, Hernández PC, Ramón RLG, Ávila COM, Hernández RP, Montero CJE, Hernández CP

Language: Spanish
References: 16
Page: 257-264
PDF size: 89.56 Kb.

ABSTRACT

CD6 molecule is a membrane glycoprotein considered a leukocyte differentiation antigen. Itolizumab, humanized monoclonal antibody (anti-CD6) recognizes the human CD6 molecule in malignant peripheral mononuclear cells of patients with B-cell chronic lymphocytic leukemia and in lymphocytes of cutaneous lesions in patients with cutaneous T- cell lymphoma. We describe preliminary results of 3 patients with B-cell chronic lymphocytic leukemia treated with itolizumab at a weekly dose of 0.8 mg/kg/dose for 12 weeks. Product administration safety was evaluated in patients with CD6+ lymphoproliferative disorders and preliminary evidence of therapeutic effect of the drug was obtained. In 100% of the patients the onset of fever and chills associated to the first infusion were reported. No serious adverse effects were observed. All patients evaluated had at least some clinical or hematological improvement.

REFERENCES

1. Singer NG, Fox DA, Haqqi TM, Beretta L, Endres JS, Prohaska S, et al. CD 6: expression during development, apoptosis and selection of human and mouse thymocytes. Int Immunol. 2002 Jun;14(6):585-97. PMID: 12039910.

2. Gimferrer I, Calvo M, Mittelbrum M, Farnós M, Sarrías MR, Enrich C, et al. Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol. 2004 Aug 15;173(4):2262-70.

3. Socarrás BB, del Valle LO, Macías C, Marsán V, Sánchez M, Lam RM, et al. Expresión fenotípica de las moléculas CD5 y CD6 en la leucemia linfoide crónica BCD5+. Rev Cubana de Hematol Inmunol Hemoter. 2009;25(1):1-6.

4. Osorio LM, De Santiago A, Aguilar- Santelises M, Mellstedt H, Jondal M. CD 6 ligation modulates the bcl- 2/ Bax ratio and protects chronic lymphocytic leukemia B cell from apoptosis induced by anti- Igm. Blood. 1997 Apr 15;89(8):2833- 41. PMID: 9108402.

5. Rodríguez T, García CA, Vázquez AM, Tormo B, Gavilondo J. Obtención de hibridomas de ratón productores de anticuerpos monoclonales que reconocen células humanas de origen T. Interf y Biotecnol. 1985;2(1):41- 51.

6. Alonso R. Caracterización del anticuerpo monoclonal humanizado T1h específico por la molécula CD 6 humana (tesis de maestría). La Habana: Centro de Inmunología Molecular; 2007.

7. García CA, Faxas ME, Gavilondo J, Amador JF, Expósito G. Topical treatment of Cutaneous T- cell Lymphoma skin lesions with the mouse anti- CD6 monoclonal antibody ior- t1 [online]. Biotecnol Apl. May-Ago 1990 [citado 2011 Mar 22];7(2):176-81.

8. Tormo BR, García CA, Chong A, Ochoa C, Faxas ME, Sagaró B, et al. Immunohistopatology of cutaneous T- cell lymphomas treated with topic ior t1 (anti CD6) monoclonal antibody. Biotecnol Apl. 1994;11(1):20- 3.

9. Faxas ME, Barroso M, Ortiz AR, García CA. Observaciones clínicas de la fase I con el anticuerpo monoclonal ior-t1 en pacientes con linfoma T cutáneo. Rev Cubana Oncol. 1999;15(1):36-42.

10. Atmar J. Review of the safety and feasibility of rapid infusion of rituximab. J Oncol Pract. 2010 Mar;6(2):91-3. doi: 10.1200/JOP.200001.

11. Prada DM, Molinero C, Torres R, López AM, Gómez JA, Hernández IM, et al. Observaciones clínicas en pacientes con artritis reumatoide tratados con anticuerpo monoclonal T1h (anti CD6). Rev Cubana de Reumatol. 2009;11(13-14):16-25.

12. Anand A, Assudani D, Nair P, Krishnamurthy S , Deodhar S, Arumugam M, et al. Safety, Efficacy and pharmacokinetics of T1h, a humanized anti-CD6 monoclonal antibody, in moderate to severe chronic plaque psoriasis -Results from a randomized phase II trial. J Immunol. 2010;184,96-113.

13. Rodriguez PC, Torres- Moya R, Reyes G, Molinero C, Prada D, Lopez AM, et al. A clinical exploratory study with itolizumab, an anti- CD 6 monoclonal antibody, in patients with rheumatoid arthritis. Results in Immunology. 2012;2:204-11.

14. Sturm I, Oertel J, Oertel S, Westermann J, Pezzutto A. Succesful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B- cell- lineage: a case report. J Medical Case Reports. 2008;2:275.

15. Wiernik P, Adiga G. Single- agent rituximab in treatment-refractory or poor prognosis patients with chronic lymphocytic leukemia. CMRO. October 2011;27(10):1987-93.

16. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood. November 2010;116(19):3705-14.